CVRx to Participate in Upcoming Investor Conferences
Key Highlights
- ➤CVRx management to attend Canaccord Genuity Medtech Forum on Nov. 11, 2026
- ➤CVRx management to present at Jefferies Global Healthcare Conference on Nov. 19, 2026
- ➤Barostim is FDA-approved for U.S. heart failure patients
- ➤Barostim holds CE Mark approval for heart failure and resistant hypertension
MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the following investor conferences: * Canaccord Genuity Medtech, Diagnostics & Digital Health Services Forum in New York on Wednesday, Nov. 11, 2026. The fireside chat is scheduled at 8:00 a.m. (ET) the same day via webcast. * Jefferies Global Healthcare Conference in London on Thursday, Nov. 19, 2026. The Company's presentation will begin at 1:00 p.m. (GMT) / 9:00 a.m. (ET) the same day via webcast. A live webcast of the events can be found at ir.cvrx.com. An archived version of the presentation will be available following the live events and can be accessed at the same location for a limited time.
Get started
Create a free account to read the full story.
